Spinal muscular atrophy with lower extremity predominance: Difference between revisions
No edit summary Tag: Manual revert |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{Short description|A rare genetic disorder affecting motor neurons}} | ||
| | |||
}} | |||
'''Spinal muscular atrophy with lower extremity predominance''' is | '''Spinal muscular atrophy with lower extremity predominance''' (SMA-LED) is a rare genetic disorder characterized by progressive muscle weakness and atrophy, primarily affecting the lower limbs. This condition is a subtype of [[spinal muscular atrophy]] (SMA), which is a group of inherited diseases that cause muscle degeneration and weakness due to the loss of motor neurons in the spinal cord and brainstem. | ||
==Genetics== | |||
SMA-LED is typically inherited in an [[autosomal dominant]] manner, meaning that a single copy of the mutated gene in each cell is sufficient to cause the disorder. The condition is often associated with mutations in the [[DYNC1H1]] gene, which encodes a protein that is part of the cytoplasmic dynein complex. This complex is crucial for intracellular transport processes, including the movement of organelles and other cargo along microtubules. | |||
==Pathophysiology== | |||
The mutation in the [[DYNC1H1]] gene leads to dysfunction in the dynein motor protein complex, impairing the transport of essential cellular components within motor neurons. This disruption in cellular transport results in the degeneration of motor neurons, particularly those that innervate the lower extremities, leading to muscle weakness and atrophy. | |||
== | ==Clinical Features== | ||
Individuals with SMA-LED typically present with muscle weakness that is more pronounced in the lower limbs than in the upper limbs. The onset of symptoms can vary, but it often occurs in childhood or adolescence. Common clinical features include: | |||
* | * Difficulty walking or running | ||
* Frequent falls | |||
* Muscle atrophy in the legs | |||
* Reduced or absent deep tendon reflexes | |||
In some cases, individuals may also experience mild weakness in the upper limbs, but this is less common. | |||
==Diagnosis== | |||
The diagnosis of SMA-LED is based on clinical evaluation, family history, and genetic testing. Electromyography (EMG) and nerve conduction studies may be performed to assess the electrical activity of muscles and the speed of nerve signals. Genetic testing can confirm the presence of mutations in the [[DYNC1H1]] gene or other associated genes. | |||
==Management== | |||
There is currently no cure for SMA-LED, and treatment is primarily supportive. Management strategies may include: | |||
* Physical therapy to maintain muscle strength and flexibility | |||
* Orthopedic interventions, such as braces or orthotics, to support mobility | |||
* Occupational therapy to assist with daily activities | |||
* Regular monitoring by a multidisciplinary team to address any complications | |||
==Prognosis== | |||
The prognosis for individuals with SMA-LED varies depending on the severity of the condition and the age of onset. While the disease is progressive, many individuals maintain a degree of mobility and independence with appropriate management. | |||
==Related pages== | |||
* [[Spinal muscular atrophy]] | |||
* [[Motor neuron disease]] | |||
* [[Genetic disorders]] | |||
[[Category:Genetic disorders]] | |||
[[Category:Neurological disorders]] | |||
[[Category:Rare diseases]] | |||
Latest revision as of 19:23, 22 March 2025
A rare genetic disorder affecting motor neurons
Spinal muscular atrophy with lower extremity predominance (SMA-LED) is a rare genetic disorder characterized by progressive muscle weakness and atrophy, primarily affecting the lower limbs. This condition is a subtype of spinal muscular atrophy (SMA), which is a group of inherited diseases that cause muscle degeneration and weakness due to the loss of motor neurons in the spinal cord and brainstem.
Genetics[edit]
SMA-LED is typically inherited in an autosomal dominant manner, meaning that a single copy of the mutated gene in each cell is sufficient to cause the disorder. The condition is often associated with mutations in the DYNC1H1 gene, which encodes a protein that is part of the cytoplasmic dynein complex. This complex is crucial for intracellular transport processes, including the movement of organelles and other cargo along microtubules.
Pathophysiology[edit]
The mutation in the DYNC1H1 gene leads to dysfunction in the dynein motor protein complex, impairing the transport of essential cellular components within motor neurons. This disruption in cellular transport results in the degeneration of motor neurons, particularly those that innervate the lower extremities, leading to muscle weakness and atrophy.
Clinical Features[edit]
Individuals with SMA-LED typically present with muscle weakness that is more pronounced in the lower limbs than in the upper limbs. The onset of symptoms can vary, but it often occurs in childhood or adolescence. Common clinical features include:
- Difficulty walking or running
- Frequent falls
- Muscle atrophy in the legs
- Reduced or absent deep tendon reflexes
In some cases, individuals may also experience mild weakness in the upper limbs, but this is less common.
Diagnosis[edit]
The diagnosis of SMA-LED is based on clinical evaluation, family history, and genetic testing. Electromyography (EMG) and nerve conduction studies may be performed to assess the electrical activity of muscles and the speed of nerve signals. Genetic testing can confirm the presence of mutations in the DYNC1H1 gene or other associated genes.
Management[edit]
There is currently no cure for SMA-LED, and treatment is primarily supportive. Management strategies may include:
- Physical therapy to maintain muscle strength and flexibility
- Orthopedic interventions, such as braces or orthotics, to support mobility
- Occupational therapy to assist with daily activities
- Regular monitoring by a multidisciplinary team to address any complications
Prognosis[edit]
The prognosis for individuals with SMA-LED varies depending on the severity of the condition and the age of onset. While the disease is progressive, many individuals maintain a degree of mobility and independence with appropriate management.
